Thursday February 06, 2014

Dynamic sales growth: +11% in volume for kit sales

Marseille, February 6, 2014 - QIAGEN Marseille (Alternext - FR0010626028 - ALIPS), a subsidiary of the QIAGEN Group (previously IPSOGEN) a cancer profiling company that develops, manufactures and markets molecular diagnostic tests for leukemia and cancer, today announced revenues for the fiscal year 2013.

Total revenue for the year ended December 31st, 2013 reached 14.8 M€, compared with 13.2 M€ in 2012, an increase of +12% over last year (+13% at constant foreign exchange rate).

See press release

distributed by